CIK 0001840233 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Xilio Therapeutics, Inc.
Sign in to watch- Ticker
- XLO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851623397
- Phone
- 617-833-1027
- Business address
- 828 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-15 | Clancy Paul J Director | Grant or award · Stock Option (right to buy) | +13,200 | 13,200 | ||
| 2022-06-15 | Xu Yuan Director | Grant or award · Stock Option (right to buy) | +13,200 | 13,200 | ||
| 2022-06-15 | Bonstein Sara Director | Grant or award · Stock Option (right to buy) | +13,200 | 13,200 | ||
| 2022-06-15 | ROSS ROBERT W. Director | Grant or award · Stock Option (right to buy) | +26,400 | 26,400 | ||
| 2022-02-22 | Giovine Salvatore CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +49,500 | 49,500 | ||
| 2022-02-22 | Huber Martin H. Jr. PRESIDENT OF R&D AND CMO | Grant or award · Stock Option (right to buy) | +65,000 | 65,000 | ||
| 2022-02-22 | Russo Rene CEO AND PRESIDENT | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2022-01-04 | Xu Yuan Director | Grant or award · Stock Option (right to buy) | +26,400 | 26,400 | ||
| 2021-12-22 | Russo Rene CEO AND PRESIDENT | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2021-12-22 | Russo Rene CEO AND PRESIDENT | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2021-12-10 | Bain Capital Life Sciences Investors, LLC 10% owner | Purchase | +21,812 | $9.56 | $209K | 2,802,225 |
| 2021-12-10 | Bain Capital Life Sciences Investors, LLC 10% owner | Purchase | +3,188 | $10.24 | $33K | 2,805,413 |
| 2021-12-09 | Bain Capital Life Sciences Investors, LLC 10% owner | Purchase | +4,011 | $9.84 | $39K | 2,780,413 |
| 2021-12-08 | Bain Capital Life Sciences Investors, LLC 10% owner | Purchase | +13,458 | $9.62 | $129K | 2,776,402 |
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion | +998,544 | 998,544 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion | +998,544 | 998,544 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion | +302,588 | 1,301,132 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion | +302,588 | 1,301,132 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Purchase | +312,500 | $16.00 | $5.0M | 1,613,632 |
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Purchase | +312,500 | $16.00 | $5.0M | 1,613,632 |
Page 9 of 12 · 224 trades